\
&
Contact us
\
&
Contact us
Published on | 3 years ago
ProgrammesThere is 1 attachment connected to this article.
Attachments are only accessible for people with an account on the NCP Flanders website.
NCP Flanders has prepared a video series and accompanying slide deck which takes stakeholders through the basics of proposal writing under Pillar II of the Horizon Europe programme with focus on Research and Innovation Actions (RIA) & Innovation Actions (IA). You can find the video series under the video section of our website here. The materials are intended for personal use and viewing only. Please don't copy or circulate without asking permission.
Another tool that could be helpful when preparing a proposal under Pillar II (RIA or IA) is the recently published annotated proposal template, prepared by the NCP network BRIDGE2HE. You can find this annotated template in attachment or on our website here (under documents). This document contains recommendations by NCPs and expert evaluators.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
AI Continent Deployment: Best use of technologies
The Digital Europe project LDT4SSC (Local Digital Twins for Smart and Sustainable Communities) has launched an Open Call for Pilots to engage European local and regional authorities, as well as a wide range of stakeholders, including public administrations at local, regional, and national levels, businesses, technology developers, suppliers, r... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
